(Q37784456)

23 August 2017

title

Molecular markers in gliomas: impact for the clinician (English)

1 reference

23 August 2017

Silvia Hofer

1

1 reference

23 August 2017

Andrew B. Lassman

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20809335

4 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20809335

4 July 2024

publication date

31 August 2010

1 reference

full work available at URL

23 August 2017

https://www.zora.uzh.ch/id/eprint/156217/1/ZORA_NL_156217.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20809335

4 July 2024

1 reference

23 August 2017

volume

5

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

201-210

1 reference

Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-010-0157-2

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-010-0157-2

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-010-0157-2

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-010-0157-2

Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-010-0157-2

Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-010-0157-2

Glioblastomas with an oligodendroglial component: a pathological and molecular study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-010-0157-2

Radiation-induced dementia in patients cured of brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-010-0157-2

Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-010-0157-2

Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-010-0157-2

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-010-0157-2

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-010-0157-2

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

12 December 2020

Long-term survival with glioblastoma multiforme

1 reference

12 December 2020

Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis

1 reference

12 December 2020

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma

1 reference

12 December 2020

Survey of treatment recommendations for anaplastic oligodendroglioma

1 reference

12 December 2020

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

1 reference

12 December 2020

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

12 December 2020

MGMT promoter methylation in malignant gliomas

1 reference

12 December 2020

Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.

1 reference

12 December 2020

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials

1 reference

12 December 2020

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

1 reference

12 December 2020

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

1 reference

12 December 2020

Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.

1 reference

12 December 2020

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

1 reference

12 December 2020

Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p

1 reference

12 December 2020

Malignant glioma: who benefits from adjuvant chemotherapy?

1 reference

12 December 2020

Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.

1 reference

12 December 2020

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

1 reference

12 December 2020

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

1 reference

12 December 2020

New (alternative) temozolomide regimens for the treatment of glioma

1 reference

12 December 2020

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

1 reference

12 December 2020

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

1 reference

12 December 2020

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

1 reference

12 December 2020

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

1 reference

12 December 2020

EGF mutant receptor vIII as a molecular target in cancer therapy

1 reference

12 December 2020

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

1 reference

12 December 2020

Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

1 reference

12 December 2020

Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].

1 reference

12 December 2020

Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients

1 reference

12 December 2020

Phase II trial of gefitinib in recurrent glioblastoma

1 reference

12 December 2020

The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.

1 reference

12 December 2020

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

1 reference

12 December 2020

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

1 reference

12 December 2020

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

1 reference

12 December 2020

Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.

1 reference

12 December 2020

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

1 reference

12 December 2020

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

1 reference

12 December 2020

Genetic pathways to glioblastoma: a population-based study

1 reference

12 December 2020

Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.

1 reference

12 December 2020

The 2007 WHO classification of tumours of the central nervous system

1 reference

12 December 2020

Successful chemotherapy for recurrent malignant oligodendroglioma

1 reference

12 December 2020

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

1 reference

12 December 2020

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma

1 reference

12 December 2020

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments

1 reference

12 December 2020

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas

1 reference

12 December 2020

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up

1 reference

12 December 2020

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

1 reference

12 December 2020

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

1 reference

12 December 2020

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

1 reference

12 December 2020

Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma

1 reference

12 December 2020

What is an oligodendroglioma?

1 reference

12 December 2020

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

1 reference

12 December 2020

IDH1 and IDH2 mutations in gliomas

1 reference

12 December 2020

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

1 reference

12 December 2020

MGMT: its role in cancer aetiology and cancer therapeutics

1 reference

12 December 2020

Molecular genetic alterations in glioblastomas with oligodendroglial component.

1 reference

12 December 2020

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

1 reference

12 December 2020

Successful chemotherapy for newly diagnosed aggressive oligodendroglioma

1 reference

12 December 2020

MGMT methylation: a marker of response to temozolomide in low-grade gliomas

1 reference

12 December 2020

Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome

1 reference

12 December 2020

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

1 reference

12 December 2020

Bevacizumab and recurrent malignant gliomas: a European perspective

1 reference

12 December 2020

Correlation among pathology, genotype, and patient outcomes in glioblastoma

1 reference

12 December 2020

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

12 December 2020

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

1 reference

12 December 2020

Gefitinib concentrations in human glioblastoma tissue

1 reference

12 December 2020

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

1 reference

12 December 2020

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

1 reference

12 December 2020

Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.

1 reference

12 December 2020

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

1 reference

12 December 2020

10.1007/S11523-010-0157-2

Identifiers

DOI

1 reference

23 August 2017

1 reference